AliveCor Logo

I nostri prodotti

Kardia 12L

Novità

KardiaMobile 6L
InstantQT
KardiaPro
Dispositivi ECG Kardia

Le nostre soluzioni

Screening della fibrillazione atriale
Soluzioni di integrazione dati
Fornitori di servizi sanitari
BioPharma

Informazioni

Leadership
Missione
Ricerca clinica
I nostri partner
Acquisti tutti i prodotti
Centro risorse
Phone
800934336
Contatti
AliveCor Logo
AliveCor Logo

Numero di supporto:

  • Danimarca: 80827060
  • Francia: 0805220703
  • Germania: 08001810996
  • Israele: 1809344393
  • Italia: 800934336
  • Regno Unito: 08000668028
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
    • Missione
    • Leadership
    • Ricerca
    • Carriere
    • Novità
    • Hub delle risorse
    • Domande frequenti
    • Manuali utente
    • Spedizione
    • Garanzia
    • Partner
    • Integrazione
  • Kardia by AliveCor
    • KardiaMobile 6L
    • KardiaMobile
    • KardiaCare
    • Internazionale
    • Piano di riduzione del carbonio
    • Dichiarazione sulla schiavitù moderna

Numero di supporto:

  • Danimarca: 80827060
  • Francia: 0805220703
  • Germania: 08001810996
  • Israele: 1809344393
  • Italia: 800934336
  • Regno Unito: 08000668028
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • Informativa sulla privacy
  • Sicurezza
  • Consenso informato sulla telemedicina
  • Termini
  • Accessibilità

©2024 AliveCor, Inc. Tutti i diritti riservati. Brevetti www.alivecor.com/patents. AliveCor e Kardia sono marchi di AliveCor, Inc. negli Stati Uniti e in altri paesi. Apple è un marchio registrato di Apple, Inc. negli Stati Uniti e in altri paesi. App Store è un marchio di servizio di Apple, Inc. Android è un marchio registrato di Google Inc. Google Play è un marchio registrato di Google Inc.

Torni indietro
Study Points to Mobile Device as Breakthrough for Community Screening and Stroke Prevention
SAN FRANCISCO Calif., 7 novembre 2012

Researchers validate AliveCor’s iPhone ECG device and application as highly effective tool to diagnose atrial fibrillation

AliveCor, Inc. announced today the results of a recent study presented yesterday at the American Heart Association Scientific Sessions 2012 conference in Los Angeles showed that a high-quality single-lead ECG can be quickly and easily recorded using an iPhone® with the AliveCor® medical device and application to diagnose atrial fibrillation (AF). The study concluded that the mobile device could be an innovative approach to community screening to prevent stroke.

The study, “Validation of an iPhone ECG Application Suitable for Community Screening for Silent Atrial Fibrillation: A Novel Way to Prevent Stroke,” was presented by Dr. Jerrett Lau, from Sydney, Australia. The principal investigator was Dr. Ben Freedman, MBBS, PhD, FACC, Cardiologist, Department of Cardiology, Concord Hospital and Professor of Cardiology at the University of Sydney, Sydney, Australia.

The researchers tested a novel iPhone application suitable for community use (AliveCor Heart Monitor), which records and sends a high-quality single-lead ECG to a server for automated analysis and subsequent interpretation by a physician to diagnose atrial fibrillation (AF). The study included 109 patients (70 sinus rhythm and 39 AF) who had single-lead ECGs recorded with the AliveCor Heart Monitor before a 12-lead ECG had been performed, in order to develop the optimized algorithm. The AF diagnosis was then validated in another 204 patients (48 AF).

The study results indicated that a high-quality single-lead ECG can be rapidly and simply recorded using an iPhone with the AliveCor application and Heart Monitor device to accurately diagnosis AF. The results presented during the session were statistically significant with accuracy rates of 94% and 95% for the two cardiologists interpreting the raw trace, and 97% for the automated algorithm, which was optimized to enhance sensitivity (sensitivity 98%, specificity 97%).

AF is the most common sustained arrhythmia and carries a five-fold increased risk of stroke. It is common in the elderly; previously unrecognized AF is estimated to occur in 1–2% of those over 65. A significant proportion of ischemic strokes are due to previously unrecognized AF, which is largely asymptomatic, and may therefore require community screening to detect the arrhythmia.

Until now, community ECG screening has not been considered to be a feasible approach for AF detection.

Dr. Freedman concluded of the AliveCor Heart Monitor, “At last, we have an effective and simple way to do community ECG screening for unknown atrial fibrillation, with the real potential to reduce the stroke burden.”

Authors of the study include Jerrett Lau, Nicole Lowres, Lis Neubeck, David B. Brieger, Raymond W. Sy, Concord Hospital and University of Sydney, Sydney, Australia; Connor Galloway, David E. Albert, AliveCor, Oklahoma City, OK; Ben Freedman, Concord Hospital and University of Sydney, Sydney, Australia.

Trasformiamo insieme la cura cardiovascolare

Se lei è un datore di lavoro o un pagatore in cerca di una soluzione aziendale completa per la salute del cuore, ci contatti.